New uses for new and old quinolones and the challenge of resistance.
about
Emerging mechanisms of fluoroquinolone resistanceMaintaining fluoroquinolone class efficacy: review of influencing factors.Studies on the antimicrobial properties of N-acylated ciprofloxacins.Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients.Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.Gastrointestinal tract colonization with fluoroquinolone-resistant Escherichia coli in hospitalized patients: changes over time in risk factors for resistance.The prevalence of fluoroquinolone resistance mechanisms in colonizing Escherichia coli isolates recovered from hospitalized patientsIn vitro activities of three nonfluorinated quinolones against representative bacterial isolates.In vitro antibacterial activities of AF 3013, the active metabolite of prulifloxacin, against nosocomial and community Italian isolates.Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus.In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model.Antimicrobial drug use and resistance among respiratory pathogens in the community.Resistance among Streptococcus pneumoniae: Implications for drug selection.Delafloxacin for the treatment of respiratory and skin infections.Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections.Comparative antibiotic resistance of diarrheal pathogens from Vietnam and Thailand, 1996-1999In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.Safety of fluoroquinolones: An updateFunctional cloning and characterization of the multidrug efflux pumps NorM from Neisseria gonorrhoeae and YdhE from Escherichia coli.Multiplex Real-Time Polymerase Chain Reaction-Based Method for the Rapid Detection of gyrA and parC Mutations in Quinolone-Resistant Escherichia coli and Shigella sppClinical Benefit of Appropriate Empirical Fluoroquinolone Therapy for Adults with Community-Onset Bacteremia in Comparison with Third-Generation-Cephalosporin Therapy.Fluoroquinolone disposition: identification of the contribution of renal secretory and reabsorptive drug transporters.Development of novel antibacterial drugs to combat multiple resistant organisms.Exploration of fluoroquinolone resistance in Streptococcus pyogenes: comparative structure analysis of wild-type and mutant DNA gyrase.Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections.Efflux pump induction by quaternary ammonium compounds and fluoroquinolone resistance in bacteria.Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: Part I gram positive bacteria.Ciprofloxacin and ceftriaxone alter cytokine responses, but not Toll-like receptors, to Salmonella infection in vitro.Fluoroquinolone antimicrobial drugs.In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014Longitudinal trends in antimicrobial susceptibilities across long-term-care facilities: emergence of fluoroquinolone resistance.The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children?Fluoroquinolone treatment of community-acquired pneumonia: a meta-analysis.Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy.Effect of quinolone treatment on selection and persistence of quinolone-resistant Escherichia coli in swine faecal flora.History of antibiotics: from fluoroquinolones to daptomycin (Part 2).Serious complications of bacteremia caused by Viridans streptococci in neutropenic patients with cancer.Impact of low-level fluoroquinolone resistance genes qnrA1, qnrB19 and qnrS1 on ciprofloxacin treatment of isogenic Escherichia coli strains in a murine urinary tract infection model.Oxidation of ofloxacin by Oxone/Co(2+): identification of reaction products and pathways.
P2860
Q24644842-8BCF2D84-A5F1-4ABD-A278-808A6C14562FQ30310427-C5111D04-EC2C-4A6C-AFFB-75F786BF5EC8Q31096940-3B496BE1-0CCA-4E3E-BF0C-A0576077362AQ31918096-7462520F-B8A8-41E8-AC85-C272A4C1C987Q33559055-3E8C5F50-3F72-4CAB-B4AF-D930D918220EQ33905604-5B87A4FF-A48A-4D10-8883-293C8C6EEE55Q33964949-415970EC-1284-4EEA-8B69-6F6667F7A6EBQ33982431-259B1C62-D84F-4C2F-8822-A35666872202Q33983727-F4C834EF-18B5-45BA-9A3B-6C7D185F8251Q34107094-AA3CF286-980B-4618-BF1B-5A43ACF5134DQ34301493-84CAFF98-99EA-4EEB-9A4A-9B3ECFBFA0FAQ34347901-00D945ED-8056-461B-9B92-C437F738A149Q34658646-265427B2-7357-4566-88F6-69D939EB464FQ34667588-0660066D-36AC-40CF-8949-700AD1B8B7EEQ35164756-3D8A70F8-39DE-42CA-A3F9-4579EF16BC02Q36014922-6A22377C-16B8-46CC-B2F0-C723FE1313F7Q36048301-A6DA5F85-A4D0-435C-95CA-2C645E5D66B6Q36170467-DD7D7296-3CE8-4FAC-9029-4BC1340630D7Q36870946-63AAE1F8-36AB-4B7A-8182-5CADD1FB14D9Q37105792-A8E8D41A-BC38-4FE7-9B3E-88D0783AECA8Q37612940-732ED2FB-F6D8-4D42-8935-D0B07A1B20C0Q37995676-7906C42A-58B5-4C72-BE7B-28A8EA1A3D41Q38350301-70E74EBA-BAEF-42BB-AFBF-749B73A5F424Q38408892-B6BC421A-F4DD-4A34-9569-22E93B849ADCQ38648594-9BFCBDCF-B25F-4F57-B919-4C8AF624E0A3Q38671076-DF308D65-505F-4E1A-B4EA-7EB3291C9BF4Q38692072-C948FD8A-489A-4A32-8B4B-1E2132087AA2Q38778418-7EBD2491-1024-4CE0-AB8A-9AE37EA92F42Q40230649-1C9F006D-8237-4932-9DA5-6CEE2B50E33AQ40342746-768F2FD2-7139-4745-A094-F5BDA3281E07Q40448254-76D7D04D-DAA6-4C13-B169-A887DBC1A787Q40636919-B7ABEB86-FF16-4465-A774-9918EFB77F78Q44229940-32F49146-AFCF-4811-BB1B-600B8279580DQ46687276-B733574B-063A-4AE6-A953-A369C64AF05FQ46702819-1F6377EC-335A-4177-BBF5-A0888F02A760Q48202873-A355DEC8-B609-4425-B1C1-0A7344401D62Q54030467-1EA290B5-0BEB-47F1-A837-1E93E77C843BQ54334733-AA59AEAF-6A87-4370-B5FB-35AA845161B3Q54671560-F9C6AA0F-C47C-4556-897F-4A742C8DCE46
P2860
New uses for new and old quinolones and the challenge of resistance.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
New uses for new and old quinolones and the challenge of resistance.
@ast
New uses for new and old quinolones and the challenge of resistance.
@en
type
label
New uses for new and old quinolones and the challenge of resistance.
@ast
New uses for new and old quinolones and the challenge of resistance.
@en
prefLabel
New uses for new and old quinolones and the challenge of resistance.
@ast
New uses for new and old quinolones and the challenge of resistance.
@en
P356
P1476
New uses for new and old quinolones and the challenge of resistance.
@en
P2093
D C Hooper
P304
P356
10.1086/313677
P407
P577
2000-02-01T00:00:00Z